Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Pick Your Top Method for starting the Morning - 2NASA's Artemis 2 moon launch seen from space | Space photo of the day for April 2, 2026
- 3Washington resident is infected with a different type of bird flu
- 4Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- 5Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- EU delegation urges China to tighten export controls
- Finding the Universe of Computer generated Reality: Individual Encounters
- Figure out how to Keep up with Your Dental Inserts for Long haul Achievement
- Photos: Presidential turkey pardons — a look back
- What's going around right now? COVID, flu, stomach bug on the rise
- Windows to the Previous: An Excursion Through the World's Notable Engineering
